NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in <i>In Vivo</i> Models of AML and ALL

Eliana Ruggiero, Birgit C. Schultes, Aaron Prodeus et al.|Blood|2020

Cited by 1